EREmily Reeves

Emily Reeves

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Emily Reeves has a total of 74 co-authors. Here are the top co-authors by number of shared publications:

  • Amanda Cohn

    Division of Birth Defects and Infant Disorders, National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, GA (Ms Neelam; Drs Olsen, Woodworth, Cohn, and Gilboa; and Ms Tong)

    2 shared publications
  • Aron J. Hall

    Coronavirus and Other Respiratory Viruses Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA (Dr Hall)

    2 shared publications
  • Ayomide Sokale

    Philadelphia Department of Public Health, Philadelphia, PA (Ms Sokale)

    2 shared publications
  • Charise J. Fox

    Eagle Global Scientific, LLC, Atlanta, GA (Ms Reeves, Dr Carlson, and Ms Fox)

    2 shared publications
  • Christina Janise McIntyre

    Midwestern State University

    2 shared publications
  • Eirini Nestoridi

    Massachusetts Department of Public Health, Boston, MA (Dr Nestoridi)

    2 shared publications

Latest Publications

  • Influenza Vaccine Effectiveness Against Influenza-Associated Hospitalizations and Emergency Department or Urgent Care Encounters Among Children and Adults—VISION, United States, 2024–2025 Season

    by Jennifer DeCuir, Emily L Reeves, Zachary A Weber, Duck-Hye Yang, Stephanie A Irving, Sara Y Tartof, Nicola P Klein, Shaun J Grannis, Toan C Ong, Sarah W Ball, et al.

    Background: The 2024–2025 influenza season was the most severe in the United States (US) since 2017–2018, with co-circulation of both influenza A virus subtypes (H1N1 and H3N2). Influenza vaccine effectiveness (VE) has varied by season, setting, and patient characteristics. Methods: Using electronic healthcare encounter data from 7 VISION sites in 8 US states, we evaluated influenza VE against influenza-associated hospitalizations and emergency department or urgent care (ED/UC) encounters from October 2024 to April 2025 among children aged 6 months–17 years and adults aged ≥18 years. Using a test-negative, case-control design, we compared the odds of influenza vaccination between acute respiratory illness encounters with a positive (cases) versus negative (controls) test for influenza by molecular assay, adjusting for confounders. Results: Analyses included 108 618 encounters (5764 hospitalizations and 102 854 ED/UC encounters) among children and 309 483 encounters (76 072 hospitalizations and 233 411 ED/UC encounters) among adults. Among children across care settings, 17.0% (6097/35 765) of cases versus 29.4% (21 449/72 853) of controls were vaccinated. Among adults, 28.2% (21 832/77 477) of cases versus 44.2% (102 560/232 006) of controls were vaccinated. VE was 51% (95% confidence interval [95% CI]: 41%–60%) against influenza-associated hospitalizations and 54% (95% CI: 52%–55%) against influenza-associated ED/UC encounters among children. VE was 43% (95% CI: 41%–46%) against influenza-associated hospitalizations and 49% (95% CI: 47%–50%) against influenza-associated ED/UC encounters among adults. Conclusions: Influenza vaccination provided protection against influenza-associated hospitalizations and ED/UC encounters among children and adults in the US during the severe 2024–2025 influenza season. These findings support influenza vaccination as an important tool to reduce influenza.

  • Modeling the Potential Impacts of Outpatient Antiviral Treatment in Reducing Influenza-Associated Hospitalizations in the United States

    by Sinead E Morris, Sarabeth M Mathis, Emily Reeves, Jessie R Chung, Rebecca K Borchering, Nathaniel M Lewis, Svetlana Masalovich, Shikha Garg, Timothy M Uyeki, A Danielle Iuliano, et al.

    Background: Seasonal influenza causes an estimated 120 000 to 710 000 hospitalizations annually in the United States. Treatment with antiviral medications, such as oseltamivir, can reduce risks of hospitalization among people with influenza-associated illness. The US Centers for Disease Control and Prevention recommends initiating antiviral treatment as soon as possible for outpatients with suspected or confirmed influenza who have severe or progressive illness or are at higher risk of influenza complications. Methods: We developed a probabilistic model to estimate the impact of antiviral treatment in reducing hospitalizations among US outpatients with influenza. Parameters were informed by seasonal influenza surveillance platforms and stratified by age group and whether individuals had a condition associated with higher risk of influenza complications. We modeled different scenarios for influenza antiviral effectiveness and outpatient testing and prescribing practices, then compared our results with a baseline scenario in which antivirals were not used. Results: Across the modeled scenarios, antiviral treatment resulted in 1215 to 14 184 fewer influenza-associated hospitalizations on average when compared with the baseline scenario (0.2%–2.7% reduction). The greatest effects occurred among adults aged ≥65 years and individuals with conditions associated with higher risk of influenza complications. Modeling 50% improvements in access to care, testing, prescribing, and treatment resulted in greater potential impacts, with over 71 000 (13.3%) influenza-associated hospitalizations averted on average compared to baseline. Conclusions: Our results support recommendations to prioritize outpatient antiviral treatment among older adults and others at higher risk of influenza complications. Improving access to prompt testing and treatment among outpatients with suspected influenza could reduce hospitalizations substantially.


  • Pregnancy and infant outcomes following SARS-CoV-2 infection in pregnancy during delta variant predominance – Surveillance for Emerging Threats to Pregnant People and Infants

    by Emily L. Reeves, Varsha Neelam, Jeffrey M. Carlson, Emily O. Olsen, Charise J. Fox, Kate R. Woodworth, Eirini Nestoridi, Evan Mobley, Shaila Montero Castro, Paula Dzimira, et al.


  • Open Access

    Pregnancy and Infant Outcomes Following SARS-CoV-2 Infection in Pregnancy during Delta Variant Predominance – Surveillance for Emerging Threats to Pregnant People and Infants

    by Emily L. Reeves, Varsha Neelam, Emily O. Olsen, Jeffrey M. Carlson, Charise J. Fox, Kate R. Woodworth, Eirini Nestoridi, Evan Mobley, Shaila Montero Castro, Paula Dzimira, et al.

    Background: SARS-CoV-2 infection in pregnancy is associated with an increased risk of adverse birth outcomes, such as preterm birth, stillbirth, and maternal and infant complications. Prior research suggests an increased risk of severe COVID-19 illness and stillbirth in pregnant people during the Delta variant predominance in 2021; however, those studies did not assess timing of infection during pregnancy, and few described COVID-19 vaccination status. Objective: Using a large population-based cohort, this study compared pregnancy and infant outcomes and described demographic and clinical characteristics of pregnant people with SARS-CoV-2 infection prior to and during the Delta variant period. Study Design: This retrospective cohort analysis included persons with confirmed SARS-CoV-2 infection in pregnancy from six U.S. jurisdictions reporting to the Surveillance for Emerging Threats to Pregnant People and Infants Network (SET-NET). Data were collected through case reports of polymerase chain reaction (PCR) positive pregnant persons and linkages to birth certificates, fetal death records, and immunization records to obtain outcomes and COVID-19 vaccination status. We described clinical characteristics and compared frequency of spontaneous abortion (Results: Among 57,529 pregnancy outcomes, 57,171 (99.4%) were liveborn infants, 56 (0.1%) were spontaneous abortions, and 302 (0.5%) were stillbirths. Most pregnant persons were unvaccinated at the time of SARS-CoV-2 infection, with the highest proportion in pre-Delta (99.4%) compared to Delta (78.5%). Of those with infections during Delta and who were previously vaccinated, the timing from last vaccination to infection was a median of 183 days. Compared to pre-Delta, infections during Delta were associated with a higher frequency of stillbirths (0.7% versus 0.4%, aPR 1.57, 95% CI: 1.15, 2.14) and preterm births (12.8%versus 11.9%, aPR 1.14, CI: 1.07, 1.21). The Delta period was associated with a lower frequency of NICU admission (aPR 0.72 95%, CI: 0.64, 0.79) compared to pre-Delta. During the Delta period, infection during the third trimester was associated with a higher frequency of preterm birth compared to the first andsecond trimester combined (aPR 1.42, 95% CI: 1.29,1.57). Conclusion: In this U.S.-based cohort of persons with SARS-CoV-2 infection in pregnancy, the majority were unvaccinated, and frequencies of stillbirth and preterm birth were higher during the Delta variant predominance period compared to pre-Delta. In the Delta period, frequency of preterm birth was higher among infections occurring in the third trimester versus those earlier in pregnancy. These findings confirm the risks of COVID-19 in pregnancy on adverse fetal and infant outcomes, specifically in the presence of a variant with more severe presentation.

  • Open Access

    Developing 21st Century Communication Skills Using Digital Storytelling

    by Emily Reeves, Christina J. McIntyre, Sally Henschel, Leslie Pierce

  • Lesson Plans for Moving in the Language Arts Classroom

    by Christina Janise McIntyre, Emily Reeves